SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming ESMO Breast Cancer Annual Congress 2023 taking place May 11-13, 2023, in Berlin, Germany.
Details of the ESMO Breast Cancer Annual Congress 2023 poster presentation are:
| Title: | A phase 1b/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC) (ID 406) |
| Presentation #: | 202P |
| Date: | Friday, May 12, 2023 |
| Time: | 12:15 p.m. CEST (6:15 a.m. EDT) |
A copy of the poster will be made available on Olema’s website under the Science section when it is presented at the congress. Abstracts for the posters can be found on the ESMO Breast Cancer Annual Congress website here.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
IR Contact:
Shane Kovacs, Chief Operating and Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.42 |
| Daily Change: | 0.16 3.76 |
| Daily Volume: | 609,315 |
| Market Cap: | US$328.140M |
March 18, 2025 December 10, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
